AnGes, Inc.
Stock Price Chart
2026/08/03 UpdatedPrice Trend
2026/08/03 UpdatedPrice & Trading Details
2026/08/03 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/08/01Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Intl Small Cap ETF
|
85.6K | +1.42% |
Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥67M | ¥153M | ¥644M | ¥874M |
| Gross Profit | -¥27M | ¥19M | ¥248M | ¥320M |
| Operating Income | -¥16,317M | -¥11,968M | -¥9,109M | -¥5,145M |
| Pretax Income | -¥16,317M | -¥11,968M | -¥9,109M | -¥5,145M |
| Net Income | -¥14,715M | -¥7,438M | -¥28,129M | -¥5,123M |
| EPS | -¥94.29 | -¥39.29 | -¥119.53 | -¥14.44 |
| Operating Margin | -24,331.65% | -7,822.66% | -1,415.31% | -588.64% |
| Balance Sheet | ||||
| Total Assets | ¥38,821M | ¥28,893M | ¥4,669M | ¥5,406M |
| Total Equity | ¥30,425M | ¥26,103M | ¥2,157M | ¥3,076M |
| Total Liabilities | ¥8,395M | ¥2,789M | ¥2,512M | ¥2,330M |
| Cash | ¥11,035M | ¥4,160M | ¥1,708M | ¥1,882M |
| Interest-bearing Debt | ¥1,156M | ¥363M | ¥272M | ¥54M |
| Equity Ratio | 78.37% | 90.35% | 46.19% | 56.90% |
| D/E Ratio | 0.04 | 0.01 | 0.13 | 0.02 |
| Cash Flow | ||||
| Operating CF | -¥11,214M | -¥8,746M | -¥6,613M | -¥5,750M |
| Investing CF | -¥97M | -¥357M | -¥131M | ¥19M |
| Financing CF | ¥3,573M | ¥2,036M | ¥4,202M | ¥5,902M |
| Free CF | -¥11,234M | -¥8,835M | -¥6,690M | -¥5,765M |
| Efficiency | ||||
| ROE | -48.36% | -28.49% | -1,304.33% | -166.55% |
| ROA | -37.90% | -25.74% | -602.51% | -94.77% |
Latest IR Information
-
Notice on Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Revision Clause
Disclosure of the monthly exercise status for the 46th stock acquisition rights with exercise price revision clause for July 2026. For the targeted month, the number of issued shares allotted is 0, the number of exercised stock acquisition rights is...
Read more -
Progress in BLA Application for HGF Gene Therapy Products | July 2026
Anges has decided to proceed with the BLA application for HGF gene therapy products following the Pre-BLA Meeting with the U.S. FDA. The preparation for the application is complete, with discussions on clinical, manufacturing, and quality aspects finalized. Attention should...
Read more -
Notice on Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Clauses
Read more
Latest News (5 items)
Company Information
About
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
